New study highlights changes in the management of gout and hyperuricemia among US rheumatologists and PCPs

2 March 2010

A new survey, titled TreatmentTrends: Gout and Hyperuricemia, found that, in the USA, rheumatologists and primary care physicians (PCPs) not only use different classifications for their gout patients but that these two groups often disagree on the best approach to treatment.

More than 70% of the rheumatologists felt that PCPs referred gout patients to them later than they would like, and 79% of the PCPs indicate a strong preference for treating and managing their gout patients on their own rather than referring to a rheumatology specialist, the study by BioTrends Research Group found. Another interesting finding was the higher use of colchicine during uric acid therapy initiation by rheumatologists compared to PCPs. Rheumatologists were also significantly more likely than PCPs to agree that hyperuricemia is a serious risk factor in the progression of cardiovascular disease.

Takeda's Uloric having impact, but cost an issue

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK